Veracyte: Phil Febbo

Veracyte has announced that Phil Febbo will join the company on Oct. 2 as chief scientific officer and chief medical officer (CMO), leading the company's global team of R&D, medical affairs, clinical affairs, quality, regulatory affairs, and lab director professionals. Febbo has more than 25 years of experience across academia and industry. He most recently served as CMO for Illumina. Prior to that, he was CMO for Genomic Health after leaving his academic position as professor of medicine and urology at the University of California, San Francisco Medical Center. He currently serves on the board of the Reagan Udall Foundation for the US Food and Drug Administration. Febbo holds a BA in biology from Dartmouth College and earned his MD from the University of California, San Francisco. He completed his internal medicine residency at Brigham and Women's Hospital and his medical oncology fellowship at the Dana Farber Cancer Institute.